About BioMotiv

Our Mission

BioMotiv is the mission-driven development company associated with The Harrington Project for Discovery & Development, a national initiative centered at University Hospitals in Cleveland. The company’s focus is accelerating breakthrough discoveries from research institutions into therapeutics for patients.

Our Approach

BioMotiv is advancing a portfolio of discoveries into new medicines through an innovative model that efficiently aligns capital and collaborations for the benefit of inventors and investors, and ultimately physicians and patients. Therapeutic opportunities are identified by BioMotiv through relationships with the Harrington Discovery Institute, universities and research institutions, disease foundations, and industry sources. BioMotiv has a capable and connected management team, advisory board, and Board that oversee the development, funding, active management, and partnering of the portfolio of therapeutic products.

Our Pipeline

The company is interested in all disease areas and broad classes of therapeutics–small molecules, antibodies, proteins, and nucleotides. BioMotiv seeks opportunities from the lead optimization through IND-enabling stages of pharmaceutical development. Products are advanced to pre-clinical milestones and/or through clinical “proof-of-concept”Âť stages, and then partnered with strategic partners or others for continued development and commercialization.